395 related articles for article (PubMed ID: 26564319)
1. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
2. PET Imaging of Mitochondrial Complex I with 18F-BCPP-EF in the Brains of MPTP-Treated Monkeys.
Tsukada H; Kanazawa M; Ohba H; Nishiyama S; Harada N; Kakiuchi T
J Nucl Med; 2016 Jun; 57(6):950-3. PubMed ID: 26912430
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 6-[(11)C]methyl-m-tyrosine ([(11)C]6MemTyr) for dopamine synthesis imaging in living brain using PET.
Kanazawa M; Ohba H; Iwazaki A; Kakiuchi T; Tsukada H
Bioorg Med Chem; 2015 Feb; 23(4):729-34. PubMed ID: 25596169
[TBL] [Abstract][Full Text] [Related]
5. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
6. Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys.
Kanazawa M; Ohba H; Nishiyama S; Kakiuchi T; Tsukada H
J Nucl Med; 2017 Jul; 58(7):1111-1116. PubMed ID: 28280215
[TBL] [Abstract][Full Text] [Related]
7. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
10. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
[TBL] [Abstract][Full Text] [Related]
11. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
14. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.
Nagai Y; Obayashi S; Ando K; Inaji M; Maeda J; Okauchi T; Ito H; Suhara T
Synapse; 2007 Oct; 61(10):809-19. PubMed ID: 17598150
[TBL] [Abstract][Full Text] [Related]
15. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
16. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
17. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
18. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
19. Cocaine congeners as PET imaging probes for dopamine terminals.
Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
